These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29133190)

  • 1. Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS).
    Decoster L; Kenis C; Naessens B; Houbier G; De Man M; Lambrecht G; Monsaert E; Moons V; Vergauwe P; Prenen H; Van Cutsem E; Wildiers H
    J Geriatr Oncol; 2018 Mar; 9(2):93-101. PubMed ID: 29133190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients.
    Ozcelik M; Odabas H; Ercelep O; Yuksel S; Mert AG; Aydin D; Surmeli H; Isik D; Isik S; Oyman A; Oven Ustaalioglu BB; Aliustaoglu M; Gumus M
    Clin Transl Oncol; 2016 Jun; 18(6):617-24. PubMed ID: 26459249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
    Rouyer M; Fourrier-Réglat A; Smith D; Becouarn Y; Guimbaud R; Tubiana-Mathieu N; Robinson P; Jové J; Grelaud A; Noize P; Moore N; Ravaud A
    J Geriatr Oncol; 2016 May; 7(3):187-94. PubMed ID: 27085302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
    Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.
    Houts AC; Ogale S; Zafar Y; Hubbard JM; Satram-Hoang S; Sommer N; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):16-22. PubMed ID: 29058260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study.
    François E; Mineur L; Deplanque G; Laplaige P; Smith D; Gourgou S; Tanang A; Ionescu-Goga M; Veerabudun K; Lelarge Y; Kim S; Rollot F
    Clin Colorectal Cancer; 2020 Sep; 19(3):e100-e109. PubMed ID: 32299778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
    Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.
    Passardi A; Scarpi E; Cavanna L; Dall'Agata M; Tassinari D; Leo S; Bernardini I; Gelsomino F; Tamberi S; Brandes AA; Tenti E; Vespignani R; Frassineti GL; Amadori D; De Giorgi U
    Oncotarget; 2016 May; 7(22):33210-9. PubMed ID: 27120807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
    Baraniskin A; Buchberger B; Pox C; Graeven U; Holch JW; Schmiegel W; Heinemann V
    Eur J Cancer; 2019 Jan; 106():37-44. PubMed ID: 30476731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
    Gouverneur A; Coutureau J; Jové J; Rouyer M; Grelaud A; Duc S; Gérard S; Smith D; Ravaud A; Droz C; Bernard MA; Lassalle R; Forrier-Réglat A; Noize P;
    Clin Colorectal Cancer; 2019 Mar; 18(1):e150-e162. PubMed ID: 30630730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
    Wang Z; Liang L; Yu Y; Wang Y; Zhuang R; Chen Y; Cui Y; Zhou Y; Liu T
    Cell Physiol Biochem; 2016; 39(3):1239-46. PubMed ID: 27595400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.
    Artaç M; Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2019 Jun; 50(2):214-220. PubMed ID: 29302856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.
    Gallois C; Artru P; Lièvre A; Auclin E; Lecomte T; Locher C; Marthey L; Zaimi Y; Faroux R; Pernot S; Barret M; Taieb J
    Eur J Cancer; 2019 Sep; 119():35-43. PubMed ID: 31415985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.